Sian Bigora insider trades: Processa Pharmaceuticals (PCSA) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Sian reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | PCSA | ↑ Buy | 1,971 | $2.71 | $5K | Direct | May 19, 2026 (19d) |
| Apr 15, 2026 | PCSA | ↑ Buy | 1,799 | $2.97 | $5K | Direct | Apr 17, 2026 (2d) |
| Mar 31, 2026 | PCSA | ↑ Buy | 2,107 | $2.54 | $5K | Direct | Apr 1, 2026 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PCSA insiders
Open-market trades in the last 12 months
About Sian Bigora's insider trades
Sian Bigora is Chief Development Officer at Processa Pharmaceuticals (PCSA). Since Mar 31, 2026, Sian has reported 3 open-market purchases worth $16K and no sales on SEC Form 4. In the last 12 months: 3 buys ($16K).
Their filings also include grants and awards (13 filings), option exercises (5 filings), shares withheld for taxes (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PCSA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.